Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CRISPR Therapeutics AG
  6. Summary
    CRSP   CH0334081137

CRISPR THERAPEUTICS AG

(CRSP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
64.19(c) 64.36(c) 62.61(c) 60.26(c) 62.54(c) Last
1 846 970 1 351 758 2 216 716 3 544 736 2 288 636 Volume
-1.32% +0.26% -2.72% -3.75% +3.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 904 M - -
Net income 2021 387 M - -
Net cash position 2021 2 051 M - -
P/E ratio 2021 12,7x
Yield 2021 -
Sales 2022 40,1 M - -
Net income 2022 -540 M - -
Net cash position 2022 1 642 M - -
P/E ratio 2022 -9,46x
Yield 2022 -
Capitalization 4 786 M 4 786 M -
EV / Sales 2021 3,02x
EV / Sales 2022 78,5x
Nbr of Employees 410
Free-Float 94,2%
More Financials
Company
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic... 
Read more
More about the company
Ratings of CRISPR Therapeutics AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CRISPR THERAPEUTICS AG
01/10CRISPR THERAPEUTICS : Corporate Presentation
PU
2021CRISPR THERAPEUTICS AG : Change in Directors or Principal Officers (form 8-K)
AQ
2021CRISPR Therapeutics AG Terminates Tony W. Ho as Executive Vice President, Research and ..
CI
2021Cowen Initiates Coverage on CRISPR Therapeutics With Market Perform Rating
MT
2021CRISPR THERAPEUTICS : Corporate Presentation
PU
2021CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GL
2021CRISPR Secures FDA Regenerative Medicine Advanced Therapy Status for CTX110 in B-Cell M..
MT
2021CRISPR THERAPEUTICS : Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designat..
PU
2021CRISPR THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2021CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designa..
GL
2021CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Gr..
CI
2021CRISPR Therapeutics, ViaCyte Secure Health Canada's Approval for Clinical Trial of Diab..
MT
2021CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited ..
GL
2021CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited ..
CI
2021CRISPR Therapeutics Corporate Presentation
PU
More news
News in other languages on CRISPR THERAPEUTICS AG
2021CRISPR Therapeutics AG met fin aux fonctions de Tony W. Ho en tant que vice-président e..
2021CRISPR obtient de la FDA le statut de thérapie avancée en médecine régénérative pour CT..
2021CRISPR Therapeutics et ViaCyte obtiennent l'approbation de Santé Canada pour l'essai cl..
2021Tres valores para terminar el año
2021Trois valeurs pour finir l’année
More news
Analyst Recommendations on CRISPR THERAPEUTICS AG
More recommendations
Chart CRISPR THERAPEUTICS AG
Duration : Period :
CRISPR Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 62,54 $
Average target price 152,79 $
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Samarth Kulkarni Chief Executive Officer & Director
Rodger Novak Chairman & President
Brendan Smith Senior VP, Chief Financial & Accounting Officer
Jonathan Alexander Terrett Head-Research
Stephen R. Kennedy Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CRISPR THERAPEUTICS AG-17.47%4 786
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381